Clinical Trial Update: Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1 [Phase 3]

View source ↗

Summary

A Phase 3 trial (REVIVE-1) comparing iclaprim to vancomycin for acute bacterial skin and skin structure infections has completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Skin and Skin Structure Infections

Drugs mentioned

• Iclaprim (iclaprim)

Snippet

Sponsor: Motif Bio | Conditions: Skin Structures and Soft Tissue Infections | Phase 3 | Status: COMPLETED | Results posted: 2018-06-19